• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Investigation Report on China's Olmesartan Market, 2009-2018 Product Image

Investigation Report on China's Olmesartan Market, 2009-2018

  • ID: 2770929
  • March 2014
  • Region: China
  • 40 Pages
  • China Research & Intelligence

According to statistics from WHO, one-third of the world's adults have high blood pressure. Death toll of this disease equals to half of the total number caused by stroke and heart attack.

Angiotensin II receptor antagonist (ABR) is an important product among various antihypertensive drugs. Developed by Sankyo and Forest Laboratories, olmesartan medoxomil was approved to the U.S.A. in April 2002 with the trade name ""Benicar"" and was approved to Europe in October 2002. In July 2006, it was launched in Chinese market. Olmesartan can take effect very soon with low dosage, and it has strong and lasting antihypertensive effect with few adverse reactions, especially dry cough. Also because of its excellent performance worldwide, many Chinese manufacturers applied to produce the generic drug. However, this behavior caused the noted ""composition patent"" olmesartan patent infringement case in 2006, resulting in the ""Bolar Exception"" in Chinese patent system. Although Beijing Winsunny Pharmaceutical Co., Ltd. won the trial and was approved to produce the genetic drug in 2007, they violates Sankyo's patent every time they produce or sell the product. For Beijing Winsunny Pharmaceutical READ MORE >

Note: Product cover images may vary from those shown

1 Relevant Concepts of Olmesartan
1.1 Development Process
1.2 Indication
1.3 Sales Status on the Global Market

2 Market Overview of Olmesartan in China, 2009-2013
2.1 Patent Status and ""Bolar Exception""
2.2 Major Manufacturers
2.3 Market Size

3 Investigation on Sales Value of Olmesartan in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region

4 Investigation on Market Share of Major Olmesartan Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Investigation on Market Size of Olmesartan by Dosage Form in China, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form

6 Reference Price of Olmesartan Produced by Different Enterprises in China Hospital Market
6.1 Shanghai Sankyo Pharmaceutical Co., Ltd.
6.2 Beijing Winsunny Pharmaceutical Co., Ltd.
6.3 Shanghai Sine Promod Pharmaceutical Co., Ltd.

7 Analysis on Major Olmesartan Manufacturers in China, 2009-2014
7.1 Shanghai Sankyo Pharmaceutical Co., Ltd.
7.2 Beijing Winsunny Pharmaceutical Co., Ltd.
7.3 Shanghai Sine Promod Pharmaceutical Co., Ltd.

8 Prospect of China Olmesartan Market, 2014-2018
8.1 Trend of Hypertension Incidence in China
8.2 Forecast on Market Size
8.3 Forecast on Competition Pattern

Selected Charts

Chart Olmesartan Products Approved to Market in China by 2014
Chart Sales Value of Olmesartan in Global Market, 2009-2013
Chart Sales Value of Olmesartan in China Hospital Market, 2009-2013
Chart Sales Value of Olmesartan by Region in China, 2009-2013
Chart Market Share of Olmesartan Enterprises by Sales Value in China, 2009-2013
Chart Price of Olmesartan Produced by Shanghai Sankyo Pharmaceutical Co., Ltd. in China Hospital Market, 2014
Chart Price of Olmesartan Produced by Beijing Winsunny Pharmaceutical Co., Ltd. in China Hospital Market, 2014
Chart Forecast on Market Size of Hospital-use Olmesartan in China, 2014-2018

Note: Product cover images may vary from those shown

- Shanghai Sankyo Pharmaceutical Co., Ltd.
- Beijing Winsunny Pharmaceutical Co., Ltd.
- Shanghai Sine Promod Pharmaceutical Co., Ltd.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

ALSO AVAILABLE IN THE FOLLOWING LANGUAGES

RELATED PRODUCTS

Our Clients

Our clients' logos